<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295502</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-9926</org_study_id>
    <secondary_id>NCI-2011-02665</secondary_id>
    <secondary_id>CDR0000695304</secondary_id>
    <secondary_id>GOG-9926</secondary_id>
    <secondary_id>GOG-9926</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT01295502</nct_id>
  </id_info>
  <brief_title>Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer</brief_title>
  <official_title>A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best dose of paclitaxel and carboplatin&#xD;
      after cisplatin and radiation therapy in treating patients with stage IB-IVA cervical cancer.&#xD;
      Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells, by stopping them from&#xD;
      dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to&#xD;
      kill tumor cells. Giving paclitaxel and carboplatin after cisplatin and radiation therapy may&#xD;
      kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of&#xD;
      adjuvant carboplatin and paclitaxel chemotherapy following concurrent weekly cisplatin&#xD;
      chemotherapy and extended field radiation in women with newly diagnosed stage IB-IVA cervical&#xD;
      cancer, with positive para-aortic nodes.&#xD;
&#xD;
      II. To determine the feasibility of the treatment regimen over the four cycles of adjuvant&#xD;
      chemotherapy once the MTD is estimated.&#xD;
&#xD;
      III. To assess the toxicities of the treatment regimen the National Cancer Institute (NCI)&#xD;
      Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the response rate to this treatment regimen in patients with measurable disease.&#xD;
&#xD;
      II. To examine progression-free survival for one year on this treatment regimen.&#xD;
&#xD;
      III. To examine overall survival. IV. To examine the location of recurrence, loco-regional&#xD;
      versus distant for one year after completion of therapy.&#xD;
&#xD;
      V. To estimate the frequency of chronic toxicities experienced within one year of study&#xD;
      entry.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of carboplatin and paclitaxel.&#xD;
&#xD;
      Patients receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36&#xD;
      and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by&#xD;
      brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive&#xD;
      adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60&#xD;
      minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 4, 2011</start_date>
  <primary_completion_date type="Anticipated">December 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of adjuvant carboplatin and paclitaxel determined based on the dose-limiting toxicities assessed by NCI CTCAE version 4</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate in patients enrolled with measurable disease</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be tabulated overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Time from study entry to time of progression or death, whichever occurs first, assessed at 1 year</time_frame>
    <description>PFS will be summarized using Kaplan-Meier plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from study entry to time of death or the date of last contact, assessed up to 1 year</time_frame>
    <description>Survival will be summarized using Kaplan-Meier plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of recurrence (loco-regional versus distant) defined as newly evident disease for patients who have no evidence of disease at baseline or progressive disease for patients who have strictly non-measurable disease at baseline</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic toxicities experienced classified using the CTCAE version 4</measure>
    <time_frame>Within 1 year of study entry</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Cervical Adenosquamous Carcinoma</condition>
  <condition>Cervical Squamous Cell Carcinoma, Not Otherwise Specified</condition>
  <condition>Stage IB Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage IIA Cervical Cancer AJCC v7</condition>
  <condition>Stage IIB Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage IIIA Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage IIIB Cervical Cancer AJCC v6 and v7</condition>
  <condition>Stage IVA Cervical Cancer AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Treatment (radiation, cisplatin, paclitaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiation, cisplatin, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiation, cisplatin, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo EBRT</description>
    <arm_group_label>Treatment (radiation, cisplatin, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam Radiotherapy</other_name>
    <other_name>External Beam RT</other_name>
    <other_name>external radiation</other_name>
    <other_name>External Radiation Therapy</other_name>
    <other_name>external-beam radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Internal Radiation Therapy</intervention_name>
    <description>Undergo brachytherapy</description>
    <arm_group_label>Treatment (radiation, cisplatin, paclitaxel, carboplatin)</arm_group_label>
    <other_name>BRACHYTHERAPY</other_name>
    <other_name>internal radiation</other_name>
    <other_name>Internal Radiation Brachytherapy</other_name>
    <other_name>Radiation Brachytherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiation, cisplatin, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed cervical cancer (squamous, adenocarcinoma, or&#xD;
             adenosquamous): International Federation of Gynecology and Obstetrics (FIGO) clinical&#xD;
             stages IB, IIA, IIB, IIIA, IIIB, IVA, with positive para-aortic lymph nodes confirmed&#xD;
             by positron emission tomography (PET)/computed tomography (CT) scan, fine needle&#xD;
             biopsy, extraperitoneal biopsy, laparoscopic biopsy or lymphadenectomy&#xD;
&#xD;
          -  Patients must have a Gynecologic Oncology Group (GOG) performance status of 0-2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcl&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcl&#xD;
&#xD;
          -  Creatinine =&lt; institutional upper limit normal (ULN); Note: if creatinine &gt; ULN,&#xD;
             creatinine clearance must be &gt; 50 mL/min&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 times ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x&#xD;
             ULN&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Neuropathy (sensory and motor) =&lt; grade 1&#xD;
&#xD;
          -  Patients with ureteral obstruction must undergo stent or nephrostomy tube placement&#xD;
             prior to study entry&#xD;
&#xD;
          -  Patients must meet the pre-entry requirements&#xD;
&#xD;
          -  Patients must have signed an approved informed consent and authorization permitting&#xD;
             the release of personal health information&#xD;
&#xD;
          -  Patients of child-bearing potential must have a negative serum pregnancy test prior to&#xD;
             study entry (within 72 hours prior to initiation of study treatment) and be practicing&#xD;
             an effective form of contraception; women should not breast-feed while on this study&#xD;
&#xD;
          -  Patients must not be receiving any other investigational agent&#xD;
&#xD;
          -  Patients should have an audiogram at baseline, and patients with pre-existing hearing&#xD;
             loss or hearing loss during treatment should be assessed frequently during cisplatin&#xD;
             therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received previous pelvic or abdominal radiation, cytotoxic&#xD;
             chemotherapy, or previous therapy of any kind for this malignancy&#xD;
&#xD;
          -  Patients with active infection&#xD;
&#xD;
          -  Patients who have circumstances that will not permit completion of this study or the&#xD;
             required follow-up&#xD;
&#xD;
          -  Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal&#xD;
             transplantation, that would require modification of radiation fields&#xD;
&#xD;
          -  Patients with a history of other invasive malignancies, with the exception of&#xD;
             non-melanoma skin cancer, are excluded if there is any evidence of other malignancy&#xD;
             being present within the last five years; patients are also excluded if their previous&#xD;
             cancer treatment contraindicates this protocol therapy&#xD;
&#xD;
          -  Patients who have undergone major surgery, excluding diagnostic biopsy, within 30 days&#xD;
             (to allow for full recovery) prior to registration&#xD;
&#xD;
          -  Patients who have a significant history of cardiac disease, (i.e., uncontrolled&#xD;
             hypertension, unstable angina, congestive heart failure, or uncontrolled arrhythmias)&#xD;
             within 6 months of registration&#xD;
&#xD;
          -  Patients who have a known sensitivity reactions to products containing Cremophor EL&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecelia H Boardman</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital/Cooper Cancer Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital Cancer Center</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

